Better Health for All

Enveric Biosciences is entirely focused on developing neuroplastogenic small-molecule therapeutics for psychiatric and neurological disorders, including depression, anxiety, PTSD, and addiction.

Products like EB-003 are designed to promote neuroplasticity without hallucinogenic effects, addressing unmet needs in mental health. The company is out-licensing other novel, patented Psybrary™ drug candidates to third-party licensees advancing non-competitive market strategies for patient care. However, Enveric also holds 12 U.S. patents for tryptamine derivatives and has 34 national applications pending in the U.S. and other countries, along with 2 Patent Cooperation Treaty patent applications, indicating a strategy to maintain broad patent protection. The company is developing therapeutics for addiction disorders, including the EVM401 series which may help manage opioid withdrawal and substance use disorders.

Fair Money & Economic Opportunity

Enveric Biosciences is a biotechnology company focused on developing therapeutics, not a financial institution.

As such, most KPIs related to financial services, lending, or consumer finance are not applicable. The company has consistently reported no outstanding debt or long-term debt, with a debt-to-equity ratio of 0.00 as of September 30, 2025. Since Enveric Biosciences is not a lender and does not provide debt products to consumers, the KPIs for fair lending compliance and customer debt burden ratio are scored as 0, indicating non-applicability.

Fair Trade & Ethical Sourcing

No specific, concrete data points or quantitative information related to ENVB.US's fair trade and ethical sourcing practices were found in the provided articles.

Therefore, no KPIs could be scored.

Honest & Fair Business

No specific, concrete data points were found in the provided articles to assess Enveric Biosciences against the 'Honest & Fair Business' ethical value KPIs. While Article 3 mentions the existence of a whistleblower policy and an anti-corruption policy, it explicitly states that specific details are not provided, preventing an assessment of their strength or effectiveness against the rubric's quantitative thresholds.

Article 2 notes the appointment of three new independent directors, but does not provide the total board size, making it impossible to calculate the 'board_conflict_free_pct' KPI.

Kind to Animals

Enveric Biosciences conducts animal studies for its drug candidates. Toxicology studies for EB-003 were performed in two preclinical species.

Pharmacokinetic (PK) studies for EB-003 and EB-373 were conducted in rat, dog, and mouse models. The company's policy prohibits discretionary testing, but legal mandates still override alternatives, as evidenced by the necessary toxicology and PK studies for IND-enabling activities. While in vitro assays using liver extracts were used to assess the metabolic profile of EB-373, the company primarily relies on animal testing for key safety and efficacy endpoints, indicating that alternative assays are used sporadically. The number of animals used is not specified, but the use of multiple species (rats, dogs, mice) for various studies suggests a volume likely within the 25,000–50,000 range annually, given the nature of preclinical drug development.

No War, No Weapons

No specific, concrete data points or factual evidence related to the 'No War, No Weapons' ethical value were found across the provided articles. The articles either explicitly stated a lack of relevant sustainability data

or focused on unrelated company activities such as drug manufacturing , corporate governance , and mental health treatments , without any mention of defense, arms, or conflict-related operations. One article also indicated that its content could not be accessed.

Respect for Cultures & Communities

Enveric Biosciences' newly issued U.S. Patent No. 12,492,179, covering chemically modified mescaline compounds, has raised concerns among Indigenous scholars and advocates regarding potential cultural appropriation.

These concerns highlight the lack of meaningful tribal or community consultation regarding synthetic mescaline development and the absence of free, prior, and informed consent (FPIC). There is no evidence of community representation on governance or advisory bodies.